Compugen SVP exercises options, sells 7,875 shares
Compugen Ltd senior vice president of business development Zurit Levine reported a series of option exercises and share sales.
Rhea-AI Filing Summary
Compugen Ltd senior vice president of business development Zurit Levine reported a series of option exercises and share sales. On April 7–8, 2026, Levine exercised share options for a total of 7,875 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 7,875 Ordinary Shares in open-market transactions at prices of $2.30 and $2.42. Following these transactions, Levine directly holds 29,375 Ordinary Shares. The filing notes these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,875 shares ($12K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Levine Zurit
Role
SVP, Business Development
Sold
7,875 shs ($19K)
Approx. gross sale proceeds
$19K
Approx. exercise cost
$7K
Approx. pre-tax spread
$12K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (right to buy) | 4,375 | $0.00 | $0.00 |
| Exercise | Share Option (right to buy) | 1,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 4,375 | $0.8292 | $4K |
| Exercise | Ordinary Shares | 1,000 | $1.15 | $1K |
| Sale | Ordinary Shares | 5,375 | $2.42 | $13K |
| Exercise | Share Option (right to buy) | 2,500 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 2,500 | $0.8292 | $2K |
| Sale | Ordinary Shares | 2,500 | $2.30 | $6K |
Holdings After Transaction:
Share Option (right to buy) — 64,750 contracts (Direct);
Ordinary Shares — 29,375 shares (Direct)
Footnotes (3)
- F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
- F2. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
- F3. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
Key Figures
Shares sold: 7,875 shares
Sale prices: $2.30 and $2.42 per share
Options exercised: 7,875 options
+5 more
8 metrics
Shares sold
7,875 shares
Total Ordinary Shares sold in open-market transactions
Sale prices
$2.30 and $2.42 per share
Prices for 2,500 and 5,375 Ordinary Shares sold
Options exercised
7,875 options
Total options exercised into Ordinary Shares
Exercise prices
$0.8292 and $1.15 per share
Strike prices on exercised share options
Post-transaction holdings
29,375 Ordinary Shares
Direct holdings after final reported sale
Rule 10b5-1 plan adoption date
December 23, 2025
Plan governing the reported transactions
Option expiration
November 9, 2032
Expiration date for one exercised option grant
Option expiration
August 3, 2033
Expiration date for another exercised option grant
Key Terms
Rule 10b5-1 trading plan, Share Option (right to buy), Ordinary Shares, Exercise or conversion of derivative security, +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Exercise or conversion of derivative security regulatory
"transaction_code_description: Exercise or conversion of derivative security for Form 4 code M."
Sale in open market or private transaction regulatory
"transaction_code_description: Sale in open market or private transaction for Form 4 code S."
SVP, Business Development other
"officer_title: SVP, Business Development for reporting person Levine Zurit."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Compugen (CGEN) executive Zurit Levine report in this Form 4?
Zurit Levine reported exercising share options for 7,875 Ordinary Shares and selling 7,875 Ordinary Shares in open-market trades. These transactions converted options into shares, then into cash, while leaving direct Ordinary Share holdings at 29,375 after the reported activity.
What options did Zurit Levine exercise in the latest Compugen (CGEN) filing?
Levine exercised options covering 7,875 Ordinary Shares. The exercised options included 6,875 shares at an exercise price of $0.8292 and 1,000 shares at $1.15 per share, converting derivative positions into Ordinary Shares before the subsequent sales.
Were Zurit Levine’s Compugen (CGEN) trades made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Such pre-arranged plans schedule trades in advance, reducing the significance of the exact timing of the reported sales.
What role does Zurit Levine hold at Compugen (CGEN) according to the Form 4?
The Form 4 identifies Zurit Levine as an officer of Compugen, serving as SVP, Business Development. This officer status means Levine’s equity transactions in Compugen securities must be reported under Section 16 insider reporting rules.
AI-generated analysis. How Rhea-AI works. Not financial advice.
